Similar Posts
Induction Chemotherapy in Esophageal Cancer: Is the “Head Start” Worth the Wait?
The “In a Nutshell” Intro While definitive chemoradiotherapy (dCRT) is the gold standard for non-surgical esophageal cancer, systemic relapse remains a formidable foe for over 50% of patients. This post explores whether “bioselection” via induction chemotherapy (IC) can actually move the needle on survival or if it’s just delaying the inevitable.
Predicting Treatment Success with Lutetium-177-PSMA: New Nomograms from the VISION Trial
Treatment selection in advanced prostate cancer just got sharper. Lutetium-177-PSMA-617 (Pluvicto®) has changed the landscape for metastatic castration-resistant prostate cancer (mCRPC). But with high costs, potential toxicity, and variable responses, the million-dollar question remains: Who will actually benefit? New data published in eClinicalMedicine (October 2024) gives us the first high-quality, validated nomograms to answer this…
NAPOLI-3 Trial: A Breakthrough in Metastatic Pancreatic Cancer Treatment
Comprehensive review of NAPOLI 3 trials results
